Key facts
- This page summarizes Jeffrey M. Jonas's Form 4 filing for Sage Therapeutics, Inc. (SAGE).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 11 Jun 2024, 16:58.
Jeffrey M. Jonas - 10 Jun 2024 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)
- Reporting relationship
- Director
- Issuer ticker
- SAGE
- Reported as of
- 10 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 11 Jun 2024, 16:58:49 UTC
- Prior SEC filing
- 10 Jun 2024
- Next SEC filing
- 06 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- Brandon Marsh, as Attorney-in-Fact for Jeffrey M Jonas
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jeffrey M. Jonas filed Form 4 for Sage Therapeutics, Inc. (SAGE) on 11 Jun 2024.
Change
- Previous filing in this sequence was filed on 10 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SAGE
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +12,500
- Change %
- Price
- $0.000000
- Shares after
- 12,500
- Date
- 10 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,500
- Exercise price
- $10.90
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan in accordance with Sage's Non-Employee Director Compensation Program. The option will vest in full upon the earlier to occur of June 10, 2025 or the day immediately prior to the 2025 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date.